NextCell Pharma Q2 FY26 loss widens to SEK 11.7 million; net sales double to SEK 3 million
Reuters2026/08/27 05:31- NextCell Pharma Q2 net sales more than doubled to SEK 3 million, driven entirely by Cellaviva sales of SEK 3 million.
- Loss after financial items widened to SEK 11.7 million; cash and cash equivalents fell to SEK 21.1 million.
- Operating cash flow deepened to a SEK 11.4 million outflow, while total cash flow swung to a SEK 11.2 million outflow.
- First-half net sales climbed 18.75% to SEK 5.7 million; loss after financial items widened to SEK 22.1 million.
- Launched research-use product NextCell-Cord RUO with FUJIFILM Biosciences; rolled out NXTCL naming across drug candidates.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
